Exclusive Summary

• - Two-path indications: hospital hyponatremia generics already open; ADPKD in US/EU unlocks post-2025, enabling skinny-label now and full-label expansion later.
• - Strong clinical value: ADPKD slows renal decline (TEMPO/REPRISE; KDIGO endorsement); hyponatremia recommended when fluid restriction fails.
• - Compliance edge: US-FDA GMP, US registration, JP-compliant API supports multi-country filings and hospital access.
• - Competitive entry: hyponatremia has multiple generics, while ADPKD labels remain scarce; differentiation via quality, supply reliability, and access speed.
• - Cost advantage: ~60–90% discount vs originator, with the biggest savings in ADPKD due to very high annual brand cost.